If you made any changes in Pure these will be visible here soon.

Personal profile

Biography

Professor Andrew Spencer is Head of the Malignant Haematology and Stem Cell Transplantation Service at The Alfred Hospital, Professor of Haematology at Monash University, Head of the Myeloma Research Group and Co-Director of the ACRF Blood Cancer Therapeutics Centre at the Australian Centre for Blood Diseases, all in Melbourne, Australia.

Prof Spencer completed his medical training in clinical and laboratory haematology in Brisbane and Sydney in 1992. He then was awarded a LRF (UK) Fellowship and spent 3 years at The Royal Postgraduate Medical School, London, United Kingdom where he undertook research into B-cell clonality in chronic myeloid leukemia and was awarded a Doctorate in Medicine from the University of London. Subsequently he moved to The Alfred Hospital where he established an independent translational research program. He was appointed Head of Malignant Hematology and Stem Cell Transplantation Services in 2007 and established a first-in-human and early phase hematology clinical research unit at the hospital in 2009.

Prof Spencer has 185 peer reviewed publications with citations in excess of 12,600 and holds 4 international patents in multiple myeloma (MM) therapeutics. Since 2013 he has been an invited speaker at 40 international meetings on genomics, therapeutics and disease monitoring in MM and is an invited investigator of the International Myeloma Foundation (IMF) Black Swan Research Initiative devising and implementing global minimal residual disease strategies for MM. He serves on the scientific advisory boards of the IMF and the International Myeloma Working Group. He chairs the Myeloma and Related Diseases Registry that he established in 2012 and the Australasian Myeloma Research Consortium. He sits on the steering committee for the global MM registry initiative INSIGHT.

Research interests

The research program of Professor Andrew Spencer aims to:

(1) identify more effective and rationale novel therapeutic strategies for MM through the identification of drug resistance processes and/or biomarkers of drug responsiveness (employing transcriptional and proteomic studies in mouse models and primary tumours) with rapid translational of synergistic drug combinations into early phase investigator-initiated clinical trials, and

(2) identify mechanisms of MM disease progression, with a particular focus on the role of the cell surface phosphatase CD45, and

(3) explore the role of different modalities of minimal residual disease (MRD) detection in MM to optimise their utility in clinical practice.

Research area keywords

  • Haematology
  • biomarkers of drug responsiveness
  • blood cancer
  • bortezomib
  • clinical research
  • drug resistance
  • ell surface phosphatase CD45
  • haematological malignancies
  • mouse model
  • multiple myeloma
  • translational research
  • novel therapeutics
  • epigenetic therapy

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2010 2024

Research Output 2003 2019

A comparison of the efficacy of immunomodulatory-free regimens in relapsed or refractory multiple myeloma: a network meta-analysis

Weisel, K., Sonneveld, P., Spencer, A., Beksac, M., Rizzo, M., Xu, Y., Fahrbach, K., Gaudig, M., Slavcev, M., Dearden, L. & Lam, A., 1 Jan 2019, In : Leukemia and Lymphoma. 60, 19, p. 151–162 12 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File

DNA-repair gene mutations are highly prevalent in circulating tumour dna from multiple myeloma patients

Mithraprabhu, S., Hocking, J., Ramachandran, M., Choi, K., Klarica, D., Khong, T., Reynolds, J. & Spencer, A., 29 Jun 2019, In : Cancers. 11, 7, 14 p., 917.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File

Monitoring tumour burden and therapeutic response through analysis of circulating tumour DNA and extracellular RNA in multiple myeloma patients

Mithraprabhu, S., Morley, R., Khong, T., Kalff, A., Bergin, K., Hocking, J., Savvidou, I., Bowen, K. M., Ramachandran, M., Choi, K., Wong, B. K. L., Reynolds, J. & Spencer, A., Aug 2019, In : Leukemia. 33, 8, p. 2022-2033 12 p.

Research output: Contribution to journalArticleResearchpeer-review

Oral azacitidine (CC-486) in combination with lenalidomide and dexamethasone in advanced, lenalidomide-refractory multiple myeloma (ROAR study)

Kalff, A., Khong, T., Mithraprabhu, S., Bergin, K., Reynolds, J., Bowen, K. M., Thakurta, A., Guzman, R., Wang, M., Couto, S., Ren, Y. & Spencer, A., Jun 2019, (Accepted/In press) In : Leukemia and Lymphoma. 9 p.

Research output: Contribution to journalArticleResearchpeer-review

Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myeloma

Kumar, S. K., Grzasko, N., Delimpasi, S., Jedrzejczak, W. W., Grosicki, S., Kyrtsonis, M. C., Spencer, A., Gupta, N., Teng, Z., Byrne, C., Labotka, R. & Dimopoulos, M. A., 1 Feb 2019, In : British Journal of Haematology. 184, 4, p. 536-546 11 p.

Research output: Contribution to journalArticleResearchpeer-review